par Early Breast Cancer Trialists' Collaborative Group (EBCTCG), S;Darby, P;McGale, C;Correa, C;Taylor, Rodrigo;Arriagada, M.J.;Clarke, D;Cutter, C;Davies, M;Ewertz, J;Godwin, Richard;Gray, Kimberly;Pierce, Timothy Joseph;Whelan, Yiwei;Wang, R
;Peto,
Référence Lancet, 378, 9804, page (1707-1716)
Publication Publié, 2011-11
;Peto, Référence Lancet, 378, 9804, page (1707-1716)
Publication Publié, 2011-11
Article révisé par les pairs
| Résumé : | After breast-conserving surgery, radiotherapy reduces recurrence and breast cancer death, but it may do so more for some groups of women than for others. We describe the absolute magnitude of these reductions according to various prognostic and other patient characteristics, and relate the absolute reduction in 15-year risk of breast cancer death to the absolute reduction in 10-year recurrence risk. |



